CoChat
Sign Up
Cited by 56

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

Duhoux, Francois P., Ameye, Geneviève, Montano‐Almendras, Carmen P., Bahloula, Khadija, Mozziconacci, Marie J., Laibe, Sophy, Wlodarska, Iwona, Michaux, Lucienne, Talmant, Pascaline, Richebourg, Steven, Lippert, Eric, Speleman, Frank, Herens, Christian, Struski, Stéphanie, Raynaud, Sophie, Auger, Nathalie, Nadal, Nathalie, Rack, Katrina, Mugneret, Francine, Tigaud, Isabelle, Lafage, Marina, Taviaux, Sylvie, Roche‐Lestienne, Catherine, Latinne, Dominique, Libouton, Jeanne M., Demoulin, Jean‐Baptiste, Poirel, Hélène A., on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG‐HO)·2012·British Journal of Haematology
DOI 10.1111/j.1365-2141.2011.08918.x
Open this paper in CoChat — free account

Abstract

Summary: The PRDM16 (1p36) gene is rearranged in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) with t(1;3)(p36;q21), sharing characteristics with AML and MDS with MECOM (3q26.2) translocations. We used fluorescence in situ hybridization to study 39 haematological malignancies with translocations involving PRDM16 to assess the precise breakpoint on 1p36 and the identity of the partner locus. Reverse‐transcription polymerase chain reaction (PCR) was performed in selected cases in order to confirm the partner locus. PRDM16 expression studies were performed on bone marrow samples of patients, normal controls and CD34 + cells using TaqMan real‐time quantitative PCR. PRDM16 was rearranged with the RPN1 (3q21) locus in 30 cases and with other loci in nine cases. The diagnosis was AML or MDS in most cases, except for two cases of lymphoid proliferation. We identified novel translocation partners of PRDM16 , including the transcription factors ETV6 and IKZF1 . Translocations involving PRDM16 lead to its overexpression irrespective of the consequence of the rearrangement (fusion gene or promoter swap). Survival data suggest that patients with AML/MDS and PRDM16 translocations have a poor prognosis despite a simple karyotype and a median age of 65 years. There seems to be an over‐representation of late‐onset therapy‐related myeloid malignancies.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2011.08918.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 50

  1. 10.1182/blood-2010-08-300145 · DOI
  2. 10.1016/j.exphem.2003.08.003 · DOI
  3. 10.1038/onc.2009.381 · DOI
  4. 10.1038/sj.leu.2403136 · DOI
  5. Bene M.C., 1995, Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, 9, 1783
  6. 10.1038/sj.leu.2404529 · DOI
  7. 10.1093/hmg/ddp543 · DOI
  8. Bloomfield C.D., 1985, t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic‐clinicopathologic association, Blood, 66, 1409, 10.1182/blood.V66.6.1409.1409 · DOI
  9. 10.1016/j.semcancer.2005.01.008 · DOI
  10. 10.1200/JCO.2008.16.0259 · DOI
  11. 10.1038/ncb2101 · DOI
  12. 10.1073/pnas.0806712105 · DOI
  13. 10.1002/gcc.20611 · DOI
  14. 10.1182/blood-2005-03-1113 · DOI
  15. 10.1371/journal.pone.0026311 · DOI
  16. 10.1002/gcc.20370 · DOI
  17. 10.1016/j.acthis.2009.09.006 · DOI
  18. 10.1182/blood.V95.8.2719 · DOI
  19. International Standing Committee on Human Cytogenetic Nomenclature, 2009, ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009)
  20. Jiang G.L., 2000, The yin‐yang of PR‐domain family genes in tumorigenesis, Histology and Histopathology, 15, 109
  21. 10.1016/j.jhep.2007.12.020 · DOI
  22. 10.1016/j.pharmthera.2005.03.008 · DOI
  23. 10.1038/sj.onc.1206923 · DOI
  24. 10.1006/meth.2001.1262 · DOI · Paper page
  25. 10.1200/JCO.2010.29.2771 · DOI
  26. 10.1186/1471-2407-4-45 · DOI
  27. 10.1038/leu.2010.13 · DOI
  28. 10.1182/blood.V96.9.3209 · DOI
  29. Moir D.J., 1984, A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders, Blood, 64, 553, 10.1182/blood.V64.2.553.553 · DOI
  30. 10.1073/pnas.89.9.3937 · DOI
  31. 10.1038/nature05690 · DOI
  32. 10.1038/nature06866 · DOI · Paper page
  33. 10.1182/blood-2002-12-3944 · DOI
  34. 10.1073/pnas.91.9.4004 · DOI
  35. 10.1038/sj.onc.1206867 · DOI
  36. 10.1182/blood-2007-07-102533 · DOI
  37. 10.1002/gcc.20241 · DOI
  38. 10.1016/S0968-0004(02)02141-2 · DOI
  39. 10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0 · DOI
  40. Shing D.C., 2007, Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice, Journal of Clinical Investigation, 117, 3696
  41. 10.1038/sj.leu.2404210 · DOI
  42. 10.1016/j.bcmd.2007.11.004 · DOI
  43. Swerdlow S.H., 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
  44. 10.1074/jbc.M808989200 · DOI
  45. 10.1038/leu.2010.69 · DOI
  46. 10.1016/j.bbamcr.2007.03.016 · DOI
  47. 10.1016/j.leukres.2005.07.002 · DOI
  48. 10.1002/gcc.10176 · DOI
  49. 10.1182/blood-2003-07-2482 · DOI
  50. 10.1074/jbc.M109.056739 · DOI

Cited by

Metadata

Authors
Duhoux, F. P., Ameye, G., Montano‐Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., Wlodarska, I., Michaux, L., Talmant, P., Richebourg, S., Lippert, E., Speleman, F., Herens, C., Struski, S., Raynaud, S., Auger, N., Nadal, N., Rack, K., Mugneret, F., Tigaud, I., Lafage, M., Taviaux, S., Roche‐Lestienne, C., Latinne, D., Libouton, J. M., Demoulin, J., Poirel, H. A., & on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG‐HO)
Venue
British Journal of Haematology
Publisher
Wiley
Published
2011-11-03
Volume
156
Issue
1
Pages
76-88
ISSN
  • 0007-1048
  • 1365-2141
DOI
10.1111/j.1365-2141.2011.08918.x
Cited by
56
References
3
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review